Tags

Type your tag names separated by a space and hit enter

Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis.
Clin Neurol Neurosurg. 2017 Mar; 154:74-78.CN

Abstract

Calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) have shown promise in the preventive treatment of migraine. Therefore, we performed a meta-analysis to evaluate the efficacy and safety of CGRP mAbs for preventive treatment of migraine. Database including Ovid-SP, Cochrane Library, Pubmed and Web of Science (ISI) were systematically searched up to April 2, 2016 for randomized controlled trials(RCTs) which were dealing with the efficacy and safety of CGRP mAbs for preventive treatment of episodic migraine. Cochrane collaboration's tool for assessing risk of bias was utilized for evaluating the bias and quality of RCTs. The data was analyzed by reviewer manager 5.2. Totally, 4 literatures matched the inclusion criteria, including 4 independent RCTs and 1198 patients. Among mentioned above, AMG334 is a monoclonal antibody against CGRP receptor, but ALD403, LY2951742 and TEV-48125 are monoclonal antibody against CGRP. We found that 7mg and 21mg AMG334 couldn't reduce the monthly migraine days from baseline to week 1-4/9-12. But 70mg AMG334 could reduce the monthly migraine days from baseline to week 9-12 (MD=-1.1, 95% CI=[-2.1,-0.2]; P=0.021) significantly, as compared with placebo. Meanwhile, after pooled estimate the efficacy of CGRP mAb against CGRP, we found that CGRP mAbs improved the decrease of monthly migraine days from baseline to week 1-4, as compared with placebo (WMD=1.62, 95% CI=[1.09,2.14], I2=0%, P<0.00001). And CGRP mAbs improved the decrease of monthly migraine days from baseline to week 9-12, no matter in single dose subgroup (WMD=1.83, 95%CI=[0.06,3.60], I2=69%,P=0.04) or in multiple doses subgroup (WMD=1.77, 95%CI=[0.40,3.14], I2=61%,P=0.01). And there were no difference in incidence of adverse events between CGRP mAb group and placebo group. In conclusion, CGRP mAbs was a safety and effective preventive treatment for episodic migraine.

Authors+Show Affiliations

Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China. Electronic address: hongpeiwei1988@qq.com.Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.Xindu Hospital of Traditional Chinese Medicine, Chengdu, Sichuan, People's Republic of China.

Pub Type(s)

Journal Article
Meta-Analysis
Review

Language

eng

PubMed ID

28129635

Citation

Hong, Peiwei, et al. "Calcitonin Gene-related Peptide Monoclonal Antibody for Preventive Treatment of Episodic Migraine: a Meta Analysis." Clinical Neurology and Neurosurgery, vol. 154, 2017, pp. 74-78.
Hong P, Wu X, Liu Y. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis. Clin Neurol Neurosurg. 2017;154:74-78.
Hong, P., Wu, X., & Liu, Y. (2017). Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis. Clinical Neurology and Neurosurgery, 154, 74-78. https://doi.org/10.1016/j.clineuro.2017.01.009
Hong P, Wu X, Liu Y. Calcitonin Gene-related Peptide Monoclonal Antibody for Preventive Treatment of Episodic Migraine: a Meta Analysis. Clin Neurol Neurosurg. 2017;154:74-78. PubMed PMID: 28129635.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis. AU - Hong,Peiwei, AU - Wu,Xintong, AU - Liu,Yao, Y1 - 2017/01/22/ PY - 2016/05/30/received PY - 2017/01/04/revised PY - 2017/01/14/accepted PY - 2017/1/28/pubmed PY - 2017/3/23/medline PY - 2017/1/28/entrez KW - CGRP KW - Calcitonin gene-related peptide KW - Headache KW - Migraine KW - Monoclonal antibody KW - Preventive treatment SP - 74 EP - 78 JF - Clinical neurology and neurosurgery JO - Clin Neurol Neurosurg VL - 154 N2 - Calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) have shown promise in the preventive treatment of migraine. Therefore, we performed a meta-analysis to evaluate the efficacy and safety of CGRP mAbs for preventive treatment of migraine. Database including Ovid-SP, Cochrane Library, Pubmed and Web of Science (ISI) were systematically searched up to April 2, 2016 for randomized controlled trials(RCTs) which were dealing with the efficacy and safety of CGRP mAbs for preventive treatment of episodic migraine. Cochrane collaboration's tool for assessing risk of bias was utilized for evaluating the bias and quality of RCTs. The data was analyzed by reviewer manager 5.2. Totally, 4 literatures matched the inclusion criteria, including 4 independent RCTs and 1198 patients. Among mentioned above, AMG334 is a monoclonal antibody against CGRP receptor, but ALD403, LY2951742 and TEV-48125 are monoclonal antibody against CGRP. We found that 7mg and 21mg AMG334 couldn't reduce the monthly migraine days from baseline to week 1-4/9-12. But 70mg AMG334 could reduce the monthly migraine days from baseline to week 9-12 (MD=-1.1, 95% CI=[-2.1,-0.2]; P=0.021) significantly, as compared with placebo. Meanwhile, after pooled estimate the efficacy of CGRP mAb against CGRP, we found that CGRP mAbs improved the decrease of monthly migraine days from baseline to week 1-4, as compared with placebo (WMD=1.62, 95% CI=[1.09,2.14], I2=0%, P<0.00001). And CGRP mAbs improved the decrease of monthly migraine days from baseline to week 9-12, no matter in single dose subgroup (WMD=1.83, 95%CI=[0.06,3.60], I2=69%,P=0.04) or in multiple doses subgroup (WMD=1.77, 95%CI=[0.40,3.14], I2=61%,P=0.01). And there were no difference in incidence of adverse events between CGRP mAb group and placebo group. In conclusion, CGRP mAbs was a safety and effective preventive treatment for episodic migraine. SN - 1872-6968 UR - https://www.unboundmedicine.com/medline/citation/28129635/Calcitonin_gene_related_peptide_monoclonal_antibody_for_preventive_treatment_of_episodic_migraine:_A_meta_analysis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0303-8467(17)30009-4 DB - PRIME DP - Unbound Medicine ER -